Provepharm signs three new Proveblue distribution agreements in Europe

France-based Provepharm, a subsidiary of the Provence Technologies Group and specialized in the development of pharmaceutical applications, says it has extended its international distribution network by signing new agreements covering eight additional European countries.

Provepharm has recently concluded one licensing and distribution agreement with NordMedica for the distribution of its product Proveblue (methylene blue) in the five Scandinavian countries - Norway, Sweden, Finland, Denmark and Iceland - and has also signed agreements with A VIPharma in Greece and Cyprus, and with Fresenius Kabi Portugal for the Portuguese market. As the product is already commercialized in France, the UK and Ireland, these new agreements mean that it will now be available to one-third of Europeans (more than 175 million people).

Provepharm SAS provides Pharmacopoeial grade methylene blue, a heterocyclic aromatic chemical compound, used in human health applications as an antidote agent for methemoglobinemia; mild urinary antiseptic for cystitis treatment; ocular disinfectant; topical antiseptic; antiviral; and anti-parasitic, as well as for cognitive dysfunction.